Factors Impacting Overall and Event Free Survival Following Post-CAR T-cell Consolidative Hematopoietic Stem Cell Transplant

Hematopoietic stem cell transplant (HSCT) has curative potential in pediatric and adolescent and young adult (AYA) B-ALL patients and is generally indicated in patients 1) in first complete remission (CR) with Ph-negative ALL with minimal residual disease (MRD) positivity at the end of consolidation or who had high-risk genetic features and were MRD-positive at the end of induction),1 2) with primary induction failure and able to achieve a CR, 3) that achieve a second complete remission (CR2) after an early marrow relapse, or 4) are in a third or greater CR.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research